Both bicuspid aortic valve (BAV) and Marfan syndrome have been associated with aortic dissection risk, but it is unknown whether the presence of BAV is associated with an increased aortic risk in patients with an FBN1 gene mutation. We evaluated aortic diameters, aortic valve function, and aortic shape in Marfan syndrome patients with and without BAV and reported aortic events during follow-up.
T
he relation between bicuspid aortic valve (BAV) morphology, aortic valve dysfunction, and aortic shape remains incompletely understood. 1 BAV has been associated with monogenic thoracic aortic aneurysm, particularly when a causal mutation is identified in the gene coding for transforming growth factor beta receptor 1 or 2, 2,3 usually in concomitance with LoeysDietz Syndrome. In addition, estimates of prevalence of BAV in patients with a mutation in the FBN1 gene have widely varied. This is, however, of great importance, as both BAV and Marfan syndrome (MFS) have been associated with aortic dissection, and it is unknown whether the presence of BAV is associated with an increased risk in patients with FBN1 gene mutations, which could lead to recommendations of earlier preventive surgical replacement of the aortic root.
We took advantage of the systematic standardized transthoracic echocardiographic (TTE) evaluation of all patients who visited the Center of Reference for MFS and Related Disorders in Paris to evaluate the prevalence of BAV in this population and to report on both aortic diameter and the occurrence of aortic events in this subgroup.
METHODS Population
All patients evaluated in our clinic were considered for inclusion. All patients with an FBN1 gene mutation were included. Our national Reference Center for MFS and Related Disorders was established in 1996. The reference center offers complete diagnostic screening and follow-up (FU). In 1 day, each patient is evaluated by a cardiologist who performs a TTE examination, a genetic counselor and a geneticist (blood is drawn for DNA analysis if appropriate), an ophthalmologist who performs slit lamp examination, and a pediatrician or a rheumatologist (depending on the patient's age). A genetic test is proposed when at least 1 major criteria and 1 minor criterion (as described in the Ghent criteria) are present or for relatives of patients with known MFS. 4 Patients under 18 receive FU in our center every 2 years, which changes to every 3 years when they become adults. Only TTE measurements from our center were used in this article. Patients who miss a scheduled visit are contacted by telephone to determine the reason. In case of surgery, surgeon reports on aortic valve morphology are systematically gathered.
A specific database has been in place since the beginning of the reference center in 1996. Patients' data are prospectively entered in our database during the clinical visits and include demographic data, several measurements of aortic diameters, and a precise description of the aortic valve (see below), including the presence and type of BAV.
All patients provided their written consent to participate in the study. Institutional Review Board approval was obtained.
Aortic Valve and Aorta Evaluation
A TTE is performed at each visit to our center by trained physicians. Aortic diameters are measured using the following guidelines: maximal aortic diameter in long axis parasternal view in end diastole using the leading edge to leading edge method. 5 Echocardiography is used to determine the presence/absence of BAV and classify the type of BAV. In cases of inconclusive echocardiography, the aortic valve is considered tricuspid. The morphology of the BAV is indicated using the Sievers classification (Figure 1) . 6 In this article, we also used the classification typical versus atypical (Figure 1 ) about the orientation of the commissure to group bicuspid type with presumed similar development abnormalities. 7, 8 BAV morphology was considered typical when the commissures were at 4 to 10, 5 to 11, or 3 to 9 o'clock, (type I left coronary cuspright coronary cusp and type 0 anteroposterior) and atypical when the commissures were at 1 to 7 or 12 to 6 o'clock (type I noncoronary cusp-right coronary cusp and type 0 lateral). Aortic regurgitation (AR) and stenosis were evaluated using an integrated approach following guidelines. 9, 10 Aortic diameters (root and ascending aorta) were converted to Z scores using the Campens method. 11 A Z score of >2 SD was considered abnormal.
Statistical Analysis
Categorical variables were presented as frequencies and percentages. χ 2 test or Fisher exact test were used for betweengroup comparisons. Continuous variables were expressed as the mean±SD or the median with range and were compared using Student unpaired t test or the Mann-Whitney U test.
We used a mixed-effect nonlinear growth curve to model the aortic root diameter increase according to age and investigate the difference between patients with a BAV and patients with a tricuspid aortic valve (TAV).
The nonlinear model used was of the form: diameter= i+s×(1-exp[α×Age]), 12 where i is the predicted diameter when age=0 for an individual, s is the difference between i and the upper asymptote, and α is the rate of approach to the
CLINICAL PERSPECTIVE
Both bicuspid aortic valve (BAV) and Marfan syndrome have been considered as risk factor for aortic dilatation / dissection, and BAV has been associated with mutations responsible for Heritable Thoracic Aortic Diseases. We report that in patients with FBN1 gene mutation, aortic diameters are larger at all ages when a BAV is present and that patients with BAV tend to be operated on earlier although the diameter threshold was identical whatever the type of aortic valve (ie, BAV or tricuspid aortic valve). We found no evidence for increased aortic risk (no aortic dissection was observed in this subgroup). Our result, therefore, does not support the lowering of the aortic root diameter threshold for surgery in case of BAV in patients with Marfan syndrome related to a FBN1 mutation.
upper asymptote. The 3 parameters i, s, and α were included as fixed effects in the model. We investigated whether the parameters of the growth curve differed depending on whether patients had a BAV or TAV by adding specific terms for BAV. Additionally, gaussian random effects were added to the fixed parameters to account for the correlation arising from repeated measurements.
We used linear mixed models to assess the variation of Z score over increasing age and the difference between patients with BAV and TAV. All models included fixed effects for the intercept as well as for slope, with random gaussian effects for individual slopes and intercepts to account for the repetition of measurements within the same individuals. The association with aortic valve type was investigated using a specific intercept and slope for the bicuspid group.
We used the Akaike information criterion to identify the best model. Models were fitted using the nlmer function of the lme4 package for the nonlinear model and the lmer function for the linear model 13 and R software version 3.4.0.
14 The data will not be made available to other researchers for purposes of reproducing the results because according to French laws it would implicate a specific patient signed consent which was not anticipated at the time the data collection began.
RESULTS

Population With FBN1 Mutation and BAV
Of the 1437 patients with FBN1 mutations, 26 patients (1.8%; 95% Confidence Interval: 1.1-2.5) had a BAV. Mean age was 24.1±12.9 years at last FU for patients with both a BAV and an FBN1 gene mutation. Median FU of patients was 3 years for BAV and 5 years for TAV, and median number of aortic root measurements was 3 in both BAV and TAV patients. Familial screening performed in 38 first-degree relatives of 14 patients with FBN1 mutations and BAV led to the discovery of only one BAV (type 1 L-R in both a brother and sister carrying the FBN1 gene mutation, with unknown valve type in the transmitting father).
Associated valve disease and aortic shape are described in Figure 1 . Only one patient had aortic stenosis. No AR was found in 14 out of 26, and no more than mild AR was found in 8 out of 26. Maximal aortic diameter was observed at the aortic root level in 25 out of 26 patients (42.5±8.6 mm) with a Z score above 2 SD in all (mean Z score: 5.2±2.2 SD; 2-3 in 3, Z score ≥3 in 22). Dilatation of the ascending aorta was absent in 17 (66%), moderate (Z score 2-3) in 4 (15%), and severe (Z score>3) in 5 (19%). Aortic diameter was maximal at the level of the ascending aorta in only one patient with severe aortic stenosis that required surgery. a random effect, allowing slopes to vary between individuals ( Figure 3A) . A different intercept was suggested (although not statistically significant), as well as a different slope for the 2 groups of patients; the divergence between growth curves increased with age until an estimated mean maximum of 44.8 mm in patients with a TAV and 53.4 mm in patients with a BAV, the average difference being estimated at 8.6 mm (95% CI, 4.8-12.5; P<0.0001). 2. The normalized aortic root diameters (Z score) as a function of age were fitted by a linear model ( Figure 3B ) allowing to estimate that the normalized aortic root diameter was higher in patients with BAV compared with TAV (+1.06; 95% CI, 0.46-1.66, P=0.0006), but that the slope of Z score with age did not differ between both groups (P=0.19). These findings indicate that aortic root diameter and normalized Z score are larger at all ages in patients with BAV when compared with TAV.
Modeling the Increase of Aortic Root
Although a sex effect was observed in the prevalence of BAV (18/26 males, ie, 69%), we found no argument for a sex effect in patients with BAV and FBN1 mutation: Similar differences in aortic root diameter and normalized Z score were identified between BAV and TAV when analyzing separately men and women (Figure in the Data Supplement) demonstrating that the overall difference was not because of a confounding excess of males in the BAV group of patients. Mean age at time of surgery was 26 years in the 3 out of 8 (38%) females compared with 27 years in 7 out of 18 (39%) operated males.
After a mean follow-up of 7.1±4.6 years in our center, 10 of 26 patients (38%) with BAV and an FBN1 gene mutation underwent surgery (Figure 2 ): the 2 patients with symptomatic aortic valve dysfunction (1 aortic stenosis and 1 AR) underwent a Bentall procedure. In the absence of significant valvular dysfunction, 3 valve-sparing surgeries and 5 Bentall procedures were performed prophylactically because of aortic root dilatation. In 3 patients, maximal aortic root diameter was 
Figure 3. Aortic root diameters and Z scores in BAV (red line) and TAV (green line).
A shows the time course of aortic root diameters with fitted lines corresponding to the predicted mean population diameters in both groups. B shows the time course of aortic root Z scores with fitted lines corresponding to the predicted mean population Z scores in both groups. above 50 mm (52 mm, 54 mm, and 60 mm) and in 4 patients maximal aortic diameter was 50 mm. In 1 woman, prophylactic surgery was performed at 45 mm to allow for pregnancy. Mean age at prophylactic aortic root surgery was 26.6±10.6 years in BAV patients and 34.4±13.1 years (P=0.08) in the 242 TAV patients operated on for prophylactic surgery.
No dissection of either the ascending or the descending aorta was observed in patients with BAV and an FBN1 mutation, whereas 85 patients with TAV had a history of aortic dissection.
DISCUSSION
The results of this study indicate that:
1. The presence of BAV in patients with an FBN1 mutation is probably coincidental because the prevalence is similar to that reported in the general population. 15 2. The associated aortic dilatation in patients with BAV and an FBN1 mutation is predominantly observed at the level of the aortic root. 3. Patients with BAV and an FBN1 mutation have larger aortic root diameters than patients with TAV and an FBN1 mutation. This difference remains stable throughout life and does not seem to be associated with an increased risk of aortic dissection. This is of great importance as aortic diameter is the only indicator for risk of aortic dissection and is used to determine the timing of preventive aortic surgery. The recent recommendations from the European Society of Cardiology 16 are supported by an observational study using our database reporting that the risk for an aortic event is low when aortic diameter is below 50 mm. 17 Considering the increased risk for aortic dissection associated with the presence of BAV in the general population, 8 one could have questioned whether earlier aortic surgery was necessary in the population of MFS patients with an FBN1 mutation. The results of the present study do not support such an attitude.
In fact, the modeling of the aortic diameter with age indicates that the aortic root dilatation rate with age is similar in the FBN1 population, whether the aortic valve is BAV or TAV. This may suggest that the larger aortic root diameter observed in patients with BAV reflects aortic root anatomy alteration associated with BAV rather than a greater aortic wall weakness that would result in faster aortic root dilatation.
In the non-MFS population, aortic dilatation associated with BAV is predominantly maximal at the tubular level of the ascending aorta. However, enlargement limited to the aortic root without dilatation of the ascending tubular aorta is observed in nearly 25% of BAV patients and is called the root phenotype. The root dilatation associated with BAV is often asymmetrical, and the larger diameter orientation is related to the bicuspid valve type. 18, 19 In addition, in patients with BAV, the rate of dilation of the aorta at the root level was found to be zero or less than the rate of growth of the diameter of the ascending aorta. 20, 21 and, in children with BAV, there is no Z score progression over time at the root level while significantly progresses at the level of the ascending between the ages of 5 and 15 years. 22 A group from the Massachusetts General Hospital recently compared the aneurysmal ascending aorta of patients with BAV and TAV. Histological alterations of aortic wall were more severe in patients with TAV than BAV, including more severe atherosclerotic changes, elastic fiber, and vascular smooth muscle cell loss, as well as medial fibrosis. 23 In MFS patients with BAV, we found an additional aortic root enlargement compared with MFS patients with a TAV. All of this data is consistent with the hypothesis of an anatomic modification of the aortic root related to BAV rather than increased aortic wall fragility.
Although our study is underpowered to compare the risk of aortic dissection in MFS patients with BAV versus TAV, our observation that no aortic event, other than preventive surgery, occurred in MFS patients with BAV when a similar threshold of 50 mm was chosen also supports the idea that the optimal aortic diameter threshold for preventive aortic root surgery should not be lowered in case of BAV.
The prevalence of BAV observed in patients with an FBN1 mutation is not increased when compared with the normal population. In fact, few studies have been able to evaluate the prevalence of BAV in the normal population because of numerous difficulties. These difficulties are (1) the low prevalence of BAV which requires that a large population is studied before clear conclusions can be drawn, (2) the population studied needs to be selected without any bias associated with the presence of valvulopathy (in fact, large published cohorts of BAV included mostly patients with significant aortic valvular dysfunction), and (3) lastly, and most importantly, echocardiography is widely dependent on the quality of the image (improving with time) and the quality of the interpretation.
Our population in this regard is particularly suited for this evaluation: (1) TTE is systematically performed in our cohort of patients with an FBN1 gene mutation and is not performed because of a symptom or murmur, which avoids selection bias. (2) TTE is performed only by senior cardiologists particularly interested in the aorta that systematically report aortic valve morphology. (3) More than 1 TTE has been performed in almost all patients thanks to their MFS systematic FU. (4) Imaging quality has increased with technical improvement of echocardiography machines, and our study is a recent one. (5) The TTE results are systematically discussed during the multidisciplinary summary meetings held 1 week after examination, and another technique is used when imaging quality is not optimal or when results are questioned (either magnetic resonance imaging or computed tomography scan).
Therefore, our population may be of interest to evaluate the association between BAV, aortic dilatation phenotype, and aortic valve dysfunction. Indeed, we found the aortic root phenotype to be predominant in our MFS population. In large series of BAV patients, aortic diameter is found to be larger at the ascending aorta level in the majority of BAV patients. In our cohort, only 2 patients had AR >2, and the only patient with aortic stenosis presented with an ascending aorta larger than the aortic root. This low percentage of patients with significant aortic valve dysfunction differs from large BAV cohorts published to date and could explain the difference in the prevalence reported for the ascending aorta phenotype. This is in keeping with the hemodynamic theory of ascending aorta dilatation related to aortic valve dysfunction. 24, 25 Another factor explaining this difference may be the young age of our population.
Taken together, all of this data emphasizes the argument that aortic dilatation in BAV may, in fact, associate an anatomic modification at the root level and dilation induced by hemodynamics at the ascending tubular aorta level.
The main limitation of our study is the small number of MFS patients with a BAV. However, to our knowledge, it is the largest cohort published to date with a clinical review, systematic genetic diagnosis, and prospective clinical and echocardiographic FU.
CONCLUSIONS
Prevalence of BAV is similar in patients with MFS related to an FBN1 gene mutation and the general population, and there is no FBN1 genotype/BAV phenotype correlation suggesting coincidental occurrence. Aortic root is larger at all ages in MFS patients with BAV when compared with patients with TAV. We found a trend towards prophylactic aortic root surgery being performed at younger age, whereas similar aortic diameter thresholds were used, without occurrence of aortic dissection. We, therefore, did not find any evidence for lowering aortic diameter thresholds used to propose preventive aortic root surgery in the presence of BAV in patients with FBN1 mutations and suggest that an alteration of aortic root anatomy associated with BAV partly explains the aortic root dilatation reported in these patients. 
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